Indication
In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations

Download public summary311KB (PDF)

Download

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2127
Pharmaceutical company
Merck
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
11 February 2019
SMC meeting date:
08 January 2019
Patient group submission deadline:
05 November 2018